The F7 p.Val22Ile missense mutation affects splicing and can be counteracted by a compensatory U1snRNA

CCL18 plasma levels are increased in progressive MS patients and associated with MRI outcomes of tissue injury (P1.396)

Plasma levels of hemostasis inhibitors and MRI outcomes in multiple sclerosis (P3.368)

THE NATURAL ARG386CYS MUTATION IN THE COAGULATION FACTOR X, AS A TOOL TO INVESTIGATE DIFFERENT FX-REQUIREMENTS IN INITIATION AND PROPAGATION PHASES.

Immune response to treatment in a severe factor VII deficient patient: characterization of the inhibitory antibody and epitope-mapping

RNA−based therapeutic approaches for blood coagulation factor deficiencies caused by splicing mutations

Mutation-specific contributions to trace factor X levels account for a life-threating phenotype in a compound heterozygous factor X deficient patient

The carboxyl-terminal region is not essential for secreted and functional levels of coagulation factor X

Genetic determinants of activated factor VII antithrombin complex plasma concentration include tissue factor, factor VII and endothelial protein C receptor gene variants

Suppression of “leaky” nonsense mutations by ribosome readthrough accounts for residual factor IX levels in Haemophilia B patients

Coagulation factor VII variants resistant to inhibitory antibodies

Mapping of inhibitory antibodies directed to the carboxy-terminus of FVIIa in severe FVII deficiency with elongated C-terminal variant (p.A354V-p.P464Hfs†)

EFFECT OF SARS-CoV-2 ON THE COAGULATION CASCADE IN COVID-19 ASSOCIATED COAGULOPATHIES

Expression Profiles of the Internal Jugular and Saphenous Veins: Focus on Hemostasis Genes

Hemostasis gene expression of the internal jugular and saphenous veins

Responsiveness of hemophilia B- causing non sense mutations to ribosome readthrough-inducing drugs strictly depends on the nucleotide and prrotein context

Factor II Activity is Similarly Increased in Patients with Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele

Human protein S circulates in plasma partially bund to LDL and HDL: do PS-lipoprotein complexes mediate PS delivery within atherosclerotic plaque?

RNA-based therapeutic approaches for blood coagulation factor deficiencies caused by a splicing mutations

Activated factor VII: antithrombin complex plasma concentration in subjects with or without angiographically demonstrated coronary artery disease and myocardial infarction